JAZZ vs. MKL

In the year-to-date period, JAZZ achieves a 0.07% return, which is significantly lower than MKL's 1.16% return. Over the past 10 years, JAZZ has underperformed MKL with an annualized return of -2.88%, while MKL has yielded a comparatively higher 9.87% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Jazz Pharmaceuticals plc (JAZZ) and Markel Corporation (MKL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current JAZZ Sharpe Ratio is 0.13, which is lower than the MKL Sharpe Ratio of 1.09. The chart below compares the historical Sharpe Ratios of JAZZ and MKL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither JAZZ nor MKL has paid dividends to shareholders.

The maximum JAZZ drawdown since its inception was -96.90%, which is greater than MKL's maximum drawdown of -61.32%. Use the drawdown chart below to compare losses from any high point for JAZZ and MKL. For additional features, visit the drawdowns tool.

Jazz Pharmaceuticals plc (JAZZ) and Markel Corporation (MKL) have volatilities of 5.73% and 5.82%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Jazz Pharmaceuticals plc and Markel Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.